10x Genomics is trading 4.47% up at $62.66 after Royal Bank of Canada initiated coverage of its shares with a Sector Perform rating, equivalent to Hold. RBC set a price target of $70.00 for TXG. - The stock is trading near the upper end of its 12-month range. - Biotech sentiment is also helping, with XBI up 2.75% during the September 2 session, though the company-specific analyst action appears to be the clearest catalyst.